因塞特医疗日本公司宣布Minjuvi®(Tafasitamab)联合来那度胺获准用于治疗复发或难治性弥漫性大B细胞淋巴瘤成人患者

美股速递
Jun 19

因塞特医疗的日本子公司宣布,其药物Minjuvi®(通用名:Tafasitamab)联合来那度胺的治疗方案,已获得监管批准,用于治疗复发或难治性弥漫性大B细胞淋巴瘤的成年患者。该疗法为这一特定患者群体提供了新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10